Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01131000 · ClinicalTrials.gov registry record · Phase 3

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

A Phase 3 study of Fever, sponsored by Cumberland Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
123
Enrollment target
11
Study locations

NCT01131000: Completed Phase 3 study of Fever, sponsored by Cumberland Pharmaceuticals.

NCT01131000 is a Phase 3 study of Fever that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 123 participants, below the 593-participant average among 18 other Fever trials with a reported enrollment target (79% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01131000, a Phase 3 study of Fever, has completed, sponsored by Cumberland Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
123 participants
Enrollment target
11
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on reducing fever at 4 hours.

Conditions Studied

Interventions

  • DRUG Ibuprofen
  • OTHER Normal Saline

Study Locations (11)

Tennessee

  • Methodist Healthcare - University Hospital - Memphis
  • Vanderbilt University Medical Center - Nashville
  • Skyline Medical Center - Nashville

North Carolina

  • Moses H. Cone Memorial Hospital - Greensboro
  • Wake Forest University Health Sciences - Winston-Salem

Florida

  • Orlando Regional Medical Center - Orlando

Missouri

  • Barnes Jewish Hospital - St Louis

Texas

  • Ben Taub General Hospital - Houston

New South Wales

  • Newcastle Mater Misericordiae Hospital - New Lambton

South Australia

  • Flinders Medical Centre - Adelaide

Other

  • Mahidol University Siriraj Hospital - Bangkok

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2002-06
Est. Completion 2005-08
Phase Phase 3
Cumberland Pharmaceuticals

43 total trials

What the finished NCT01131000 record still lists

NCT01131000 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 593-participant average among 18 other Fever trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Fever appearing as the primary indexed condition, and to 2 interventions - of which Ibuprofen is the first listed.

NCT01131000 lists 11 locations in 8 states (Tennessee, North Carolina, Florida).

Frequently Asked Questions

What is clinical trial NCT01131000 about?

NCT01131000 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients". The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on reducing fever at 4 hours.

What is the current status of trial NCT01131000?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2002-06. Estimated completion is 2005-08.

What conditions does trial NCT01131000 study?

This clinical trial studies the following conditions: Fever.

What interventions are being tested in trial NCT01131000?

The interventions under investigation include: Ibuprofen (DRUG), Normal Saline (OTHER).

Who is sponsoring clinical trial NCT01131000?

This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01131000 being conducted?

This trial has 11 study locations across Florida, Missouri, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fever

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01131000's enrollment target sits among peer trials

123 10th of 18 higher than 9 of 18 other Fever trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fever trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05285891 · 123 participants · Phase 4

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  • NCT05334368 · 123 participants · Phase 3

    Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

  • NCT06088355 · 123 participants · NA

    Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

  • NCT06111131 · 123 participants · NA

    Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01131000, the US trial registry maintained by the National Library of Medicine. NCT01131000 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.